Study of RTP-026 for heart attack patients
Part of Heart & circulation clinical trials.
This trial tests a new medicine called RTP-026 for people having a serious heart attack (STEMI). It looks at whether the medicine is safe and helps the heart recover better when given along with the standard procedure to open the blocked artery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men 18 to 85 years old, or women who are past menopause and up to 85
- Chest pain that started less than 12 hours ago
- A specific type of heart attack called STEMI seen on an ECG
- You need to be able to have a procedure to open the blocked artery (primary PCI)
- Your blood test results (NLR) must be within a certain range at the hospital
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a special heart “reset” step (ischemic postconditioning) and using an imaging guide during the emergency procedure can improve outcomes for people having a STEMI heart attack. It’s meant to optimize treatment when a blocked heart artery is being opened.
This trial tests whether a half-dose medicine called r-SAK given before a primary PCI heart stent procedure improves outcomes and safety in people with a specific type of heart attack. It may help the heart recover better, but it also checks the risk of side effects like bleeding.
This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.
This study tests whether adding the drug rituximab to standard heart attack treatment can reduce damage to the heart muscle after a heart attack. Rituximab is usually used for immune system conditions, and it may help calm inflammation and protect the heart. Participants must have a certain type of heart attack and be treated quickly.
This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
Hear when a new ST Elevation Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.